Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$31.78 USD
0.00 (0.00%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $31.80 +0.02 (0.06%) 6:38 PM ET
4-Sell of 5 4
A Value B Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
COLL 31.78 0.00(0.00%)
Will COLL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for COLL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COLL
Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Lag Estimates
COLL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Unlocking Q1 Potential of Collegium Pharmaceutical (COLL): Exploring Wall Street Estimates for Key Metrics
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Other News for COLL
7 Biotech Stocks to Buy on the Dip: June 2024
IHF: Healthcare Dashboard For June
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
Collegium obtains six month extension of U.S. pediatric exclusivity for Nucynta
Jefferies upgrades Collegium to buy, cites upside related to LOEs